Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objectives— Recent studies have demonstrated a role for thiazolidinediones in attenuating atherosclerosis. However, these studies were performed in insulin-resistant animal models in association with reductions in insulin and glucose levels. To assess the vascular effects of thiazolidinediones, independent of their metabolic effects, we observed the effect of rosiglitazone on diabetes-associated atherosclerosis in a model of insulin insufficiency. Methods and Results— Control and diabetic apolipoprotein E–deficient mice received rosiglitazone or placebo. Diabetic mice demonstrated a 3-fold increase in plaque area, which was attenuated by rosiglitazone. There was no significant difference in glucose, insulin, or cholesterol levels between treated and untreated diabetic animals. Rosiglitazone attenuated the increase in superoxide production observed in diabetic mice. A 4-fold increase in the reverse cholesterol transport marker ABCA1 was observed in treated diabetic mice. Rosiglitazone reduced angiotensin II receptor gene expression in control and diabetic mice, and macrophage accumulation was increased in diabetic mice compared with controls and was attenuated by rosiglitazone. Conclusions— These findings suggest peroxisome proliferator-activated receptor-γ ligands such as rosiglitazone confer vascular protection independent of their effects on metabolic control. These antiatherosclerotic effects may have important clinical ramifications not only in insulin resistance/type 2 diabetes and also in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Touyz, R. M., Chen, X., Tabet, F., Yao, G., He, G., Quinn, M. T., Pagano, P. J., & Schiffrin, E. L. (2002) · Circulation Research · doi:10.1161/01.res.0000020404.01971.2f · Cited by 590
Cefalu, W. T., Wang, Z. Q., Bell-Farrow, A., Kiger, F. D., & Izlar, C. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.7.1317 · Cited by 92
Cited by
Macrophages in Atherosclerosis Regression
Barrett, T. J. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312802 · Cited by 628
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H. M., & Kooistra, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.142570 · Cited by 527
Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407
Self-citationTherapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
Self-citationPPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Metadata
- Authors
- Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A., & Allen, T. J.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2005-09
- Volume
- 25
- Issue
- 9
- Pages
- 1903-1909
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2152216243
- Cited by
- 128
- References
- 5
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects. https://app.cochat.ai/papers/10.1161/01.atv.0000177813.99577.6b
- The paper
- Calkin, A. C., Forbes, J. M., Smith, C. M., Lassila, M., Cooper, M. E., Jandeleit-Dahm, K. A., & Allen, T. J. (2005). Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.0000177813.99577.6b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.